LogiPharma, the world’s largest end-to-end life sciences supply chain event, has unveiled its 2025 Artificial Intelligence Report, revealing a major transition in how pharmaceutical companies are adopting AI technologies. Based on insights from 100 senior supply chain leaders across Europe and North America, the report highlights a strategic shift in investment—from monitoring to predictive intelligence.

According to Ben Sharples, Conference Director at LogiPharma, AI has moved beyond pilot phases to practical deployment, influencing nearly every area of pharma supply chains. “The industry is preparing for a complex, unpredictable world by building multi-layered resilience, prevention, and prediction,” he noted.

The report found that while real-time monitoring remains important, AI adoption is now strongest in predictive intelligence. Sixty-four percent of respondents are exploring blockchain and chain-of-custody systems, while 53% are investing in AI and ML tools for predictive risk alerts.

Key priorities include demand sensing for new product launches, personalised medicine delivery, and counterfeit detection. However, human oversight remains essential, as leaders view AI as a collaborator rather than a decision-maker.

Despite enthusiasm, challenges persist—70% of respondents cited internal resistance, 58% regulatory uncertainty, and 48% a shortage of AI-skilled professionals.

AI and digital transformation will be central themes at LogiPharma 2026 in Vienna.